NICE is unable to make a recommendation about the use in the NHS of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment because no evidence submission was received from Gilead Sciences for the technology.

  • National Institute for Health and Care Excellence (NICE)